- ≥18 years old
- HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
- Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus
fulvestrant in line with the licenced indication(s)
- No prior or current enrolment in an interventional clinical trial for ABC/MBC
- Minimum of three months of follow up data since palbociclib with fulvestrant
initiation, or minimum of six months of follow up data since palbociclib with
letrozole/aromatase inhibitor initiation (core medical record review)
- Minimum of three months of follow up data since palbociclib initiation (interim
medical record review)
- ≥18 years old
- HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
- Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus
fulvestrant in line with the licenced indication(s)
- No prior or current enrolment in an interventional clinical trial for ABC/MBC
- Minimum of three months of follow up data since palbociclib with fulvestrant
initiation, or minimum of six months of follow up data since palbociclib with
letrozole/aromatase inhibitor initiation (core medical record review)
- Minimum of three months of follow up data since palbociclib initiation (interim
medical record review)